ArticleTurkish journal of medical sciences2025
Efficacy and safety of low-power holmium laser enucleation of the prostate: experience gained from more than 700 cases.
Article in Turkish journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: The aim of this study was to investigate the functional outcomes, safety, and effectiveness of low-power (LP) holmium laser enucleation of the prostate (HoLEP) using a 37.5 W holmium laser source. Materials and methods: We retrospectively reviewed 713 patients with a diagnosis of benign prostatic hyperplasia (BPH) treated with HoLEP using an LP setting (37.5 W laser set to 1.5 J with a frequency of 25 Hz). All procedures were performed by experienced urologists. Functional outcomes, perioperative parameters, and complications were assessed over a 12-month follow-up period. Effect sizes (Cohen's d) and 95% confidence intervals (CI) were calculated to evaluate the magnitude and precision of changes in maximum urinary flow rate (Qmax), postvoiding residual volume (PVR), international prostate symptoms score (I-PSS), and other parameters. Results: The mean (SD) preoperative serum PSA level was 4.8 ng/mL (3.6), and the mean prostate volume was 94.02 mL (55.35). The average enucleation time was 72.42 min (32.36), morcellation time was 10.35 min (8.62), and total operation time was 82.74 min (38.08). At 1 month after the surgery, significant improvements were observed in I-PSS (from 25.01 (7.62) to 11.02 (5.3), Cohen's d = 2.08, 95% CI 1.91-2.25), Qmax (from 10.7 (4.28) to 18.68 (9.52) mL/s, d = 1.08, 95% CI 0.93-1.22), and PVR (from 139.38 (18.07) to 24.85 (18.07) mL, d = 3.13, 95% CI 2.87-3.39), all with p < 0.001. Transfusion was required in 23 patients (3.2%) and early reoperation in 14 patients (2%). Stress urinary incontinence occurred in 11 patients (1.5%) during late follow-up but was resolved in all cases by the 6th month. These outcomes support the safety and efficacy of LP HoLEP, yielding results comparable to those reported with high-power (HP) laser techniques in the literature. Conclusions: In this retrospective study, we showed that LP HoLEP can be performed safely and effectively, similar to other enucleation methods; however, further studies are necessary to validate its acceptance as a viable alternative to HP HoLEP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.